Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the first quarter ended March 31, 2008.

"We made significant progress in both of our development programs during the first quarter," said Steve Worland, Ph.D., President and CEO of Anadys. "We successfully completed preclinical evaluation of ANA598, our non-nucleoside polymerase inhibitor for the treatment of hepatitis C, and have subsequently filed an IND for this product candidate. We also commenced dosing with ANA773, our oral TLR7 agonist prodrug, in patients with advanced cancer." Providing an updated cash outlook for 2008, Dr. Worland added, "Based on promising results from the preclinical evaluation of ANA598, we have made the strategic decision to accelerate certain non-clinical development activities for ANA598 into 2008 and now expect our cash utilization this year to be in the range of $29 million to $31 million."

Financial Results

As of March 31, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $48.8 million compared to $56.5 million as of December 31, 2007.

During the first quarter of 2008 the Company had no revenue, compared to $1.1 million in revenue for the same quarter of 2007. The revenue in the first quarter of 2007 was primarily derived from the amortization of an upfront payment and milestone payment under a prior collaboration.

Research and development expenses were $6.0 million for the first quarter of 2008 compared to $6.7 million for the first quarter of 2007. The $0
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... made as distribution channel reorders,continue, FREDERICK, ... maker of ActiPatch(R) Therapy, the drug free ... delivering continuous pulse,therapy that revolutionizes the way ... distribution penetration into the Canadian market.,ActiPatch Therapy ...
... Consultancy for Emerging Chinese Companies, HAIKOU CITY, ... Inc. ("China Pharma") (OTC Bulletin Board: CPHI),which develops, ... China, today announced the appointment of,The Ruth Group ... Zhilin Li, President and CEO of China Pharma ...
... BURLINGAME, Calif., Oct. 21 Sensorin, which ... measurement,platform for bioprocess applications, today announced the ... Use of proceeds from the financing includes,product ... proprietary pH,sensing system. Terms of the financing ...
Cached Biology Technology:BioElectronics Announces Significant Progress in Canadian and International Distribution 2China Pharma Holdings, Inc. Appoints The Ruth Group 2China Pharma Holdings, Inc. Appoints The Ruth Group 3Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture 2
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
(Date:7/9/2014)... critically ill children with traumatic injuries have identified ... likely to develop a hospital-acquired infection. The study, ... published online in June in the journal ... that could lead to the clinical implementation of ... or reverse immune system damage following critical illness ...
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Bacteria hijack plentiful iron supply source to flourish 2
... engineers, led by the University of Alberta and the ... $3.39 million, three-year study to assess the potential effects ... "Nanotechnology is a very new and quickly developing field. ... solid scientific data upon which to base their regulatory ...
... In a discovery that rebuffs conventional scientific thinking, ... a novel way to block the activity of the ... found in children and young adults. In the ... , they report discovering and successfully testing a small ...
... 2009 Researchers at Ben-Gurion University of the Negev (BGU) ... may increase the possibility for diseases, including cancer., The findings ... Research ., The team of researchers from BGU,s National Institute ... for mutations in the genome of the mitochondria, a part ...
Cached Biology News:Canadian researchers set to study impact of nanomaterials on aquatic ecosystems 2GUMC discovery highlights new direction for drug discovery 2GUMC discovery highlights new direction for drug discovery 3Ben-Gurion U. researchers reveal connection between cancer and human evolution 2
propidium iodide *1.0 mg/mL solution in water*...
1 unit is sufficient for 1 caspase activity assay....
Applications: (+) Immunocytochemistry and immunohistochemistry...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: